-
General Session 3 includes latest results from SERENA-2, CAPItello–291, and STIC CTC trials
Thursday’s General Session included data from trials looking at the efficacy of the next-generation SERD camizestrant, the investigational AKT inhibitor capivasertib, and the use of circulating tumor cell count to guide the choice between chemotherapy and endocrine therapy.
-
Debate highlights differences and similarities between CDK4/6 inhibitors
During a Thursday debate session, Ruth O’Regan, MD, and Debra Patt, MD, PhD, MBA, argued whether the impacts of CDK4/6 inhibitors had more to do with patient selection or molecular structure and potency of agents.
-
Brinker Award recipient honored for pioneering contributions to the field of cancer genetics
Geoffrey M. Wahl, PhD, received the Brinker Award for Scientific Distinction in Basic Science on Thursday and emphasized the necessity of interdisciplinary alliances and mentorship to further scientific research.
-
Targeting the Tumor Microenvironment for Clinical Impact: Presenter Profiles
Igor Bado, PhD, and J. Javier Bravo-Cordero, PhD, preview their Friday afternoon presentations.
-
Advances in Pregnancy Associated Breast Cancer (PABC): Presenter Profile
Matteo Lambertini, MD, PhD, previews a Friday afternoon presentation on oncofertility and other quality of life issues.
-
Panel of experts to discuss advances in radiotherapy technologies, techniques for breast cancer
Wendy A. Woodward, MD, PhD, leads a session on Friday looking at technological advances in radiation oncology and the impact on both patients and clinicians.
-
Session to review latest data on the impact of targeting the tumor microenvironment in breast cancer
Diana M. Cittelly, PhD, will moderate a session on Friday looking at how the tumor microenvironment has emerged as a critical driver of tumor progression.
